Femasys Inc - SIC # 3841 - SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS

Ticker Exchange SIC # Website Latest Ticker
FEMY Nasdaq 3841 http://www.femasys.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Femasys Inc

Femasys Inc. Announces Financial Results for the Year Ended December 31, 2022 and Provides Corporate Update - Mar 30th, 2023 12:00 pm
Femasys Inc. to Participate in “The Post-Roe Fertility Journey” Panel Discussion at SXSW 2023 - Mar 9th, 2023 1:00 pm
Femasys Inc. Announces Commercial Availability of its FemCath Intrauterine Device - Dec 19th, 2022 2:00 pm
Femasys Inc. Reports Encouraging Promotional Launch of FemCerv at AAGL Based on Positive Reception by Gynecologic Physicians and Surgeons - Dec 12th, 2022 1:30 pm
Femasys Inc. Announces Enrollment is over 25% Complete for FemaSeed® De Novo Trial Following Updated Strategic Study Design - Nov 29th, 2022 12:00 pm
Femasys Inc. to Present at the Piper Sandler 34th Annual Healthcare Conference - Nov 21st, 2022 1:30 pm
Femasys Third Quarter 2022 Earnings: Misses Expectations - Nov 12th, 2022 1:17 pm
Femasys Inc. (FEMY) Reports Q3 Loss, Lags Revenue Estimates - Nov 10th, 2022 2:55 pm
Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2022 and Provides Corporate Update - Nov 10th, 2022 1:44 pm
Femasys Inc. Provides Strategic Update on its FemaSeed® Pivotal Trial Design to Expedite Clinical Program Advancement - Oct 20th, 2022 12:00 pm
Femasys to Participate in 78th Annual American Society for Reproductive Medicine (ASRM) Scientific Congress - Oct 14th, 2022 8:05 pm
Femasys Inc. Announces the Appointment of Christine Thomas as Senior Vice President of Regulatory and Clinical Affairs - Oct 12th, 2022 12:00 pm
Femasys Inc. Announces Enrollment Completion for Stage 2 Study of FemBloc for Permanent Birth Control - Oct 6th, 2022 12:01 pm
Femasys Inc. Announces the Commercial Availability of FemCerv® for Cervical Cancer Screening and Expands Management Team - Sep 29th, 2022 12:00 pm
Femasys Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference - Sep 1st, 2022 8:05 pm
Femasys Inc. (FEMY) Reports Q2 Loss, Tops Revenue Estimates - Aug 10th, 2022 9:45 pm
Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2022 and Provides Corporate Update - Aug 10th, 2022 8:05 pm
Femasys To Participate in Upcoming BTIG Biotechnology Conference - Aug 3rd, 2022 12:00 pm
Femasys To Host Key Opinion Leader Event on FemBloc, a First-of-its-Kind Medical Solution for Permanent Birth Control and an Important Option for Women Post Overturn of Roe v. Wade - Jul 20th, 2022 11:00 am
Femasys to Participate in the Women’s Health Panel Discussion Presented by Maxim Group LLC and hosted by M-Vest on Wednesday, July 13th at 11 a.m. ET - Jul 11th, 2022 12:30 pm